Pancreatic Cancer Trial, Recruiting NCT04275557 Sponsor: H. Lee Moffitt Cancer Center and Research Institute Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT04275557
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been seen at a GI clinic, surgery department, or endoscopy unit and doctors suspect or have confirmed that you have a problem with your pancreas (such as a cyst, growth, cancer, or inflammation), based on your symptoms, scans, or blood tests.
  • You have not yet had any treatment for your pancreas condition.
  • You are able to read and understand the consent form and agree to take part voluntarily.
  • You are willing to fill out study questionnaires and allow the researchers to use your medical images and/or samples (such as blood, fluid, or tissue) that are collected during your normal medical care.

Who may not be able to join:

  • You do not have any suspected or confirmed pancreas problem (such as a cyst, growth, cancer, or inflammation).
  • You have already been diagnosed with a pancreas condition and have already received treatment for it, such as surgery, chemotherapy, immunotherapy, or radiation.
  • You are not able to understand or sign the consent form.
  • You are not willing to complete the study questionnaires or share your medical samples or images with the researchers.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jennifer Permuth, PhD, Moffitt Cancer Center

Phone: 813-745-6360

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
18 February 2020
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Predictive value of CT Radiomic features vs conventional radiologic features; Development of Clinical Decision Making Models for Predicting IPMN Pathology; Radiogenomic Analyses

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov